Search results with tag "Stimulating agents"
Erythropoiesis-Stimulating Agents – Commercial Medical ...
www.uhcprovider.com“ESAs” will be used to refer to all erythropoiesis stimulating agents, unless otherwise specified. For the purposes of the Coverage Rationale, all hematocrit (Hct) values are either pretreatment (for the first 4-6 weeks of therapy) or obtained during treatment to …
RETACRIT (epoetin alfa-epbx) Billing and Coding Guide
www.pfizeroncologytogether.comclaim should include the drug code, modifier, and number of units discarded.2 When reporting the administration of erythropoiesis-stimulating agents (ESAs) on non-ESRD claims, Medicare and some payers may require modifier EA, EB, or EC to specify anemia. 3 Modifier ED or EE and GS may be used to describe
CMS Manual System
www.cms.govA. Background: The treatment of anemia in cancer patients includes the use of erythropoiesis stimulating agents (ESAs) such as recombinant erythropoietin and darbepoetin. Though other pharmacologic interventions are possible, ESAs are commonly prescribed. Recently published data regarding the use of ESAs have raised safety concerns.
Medicare Claims Processing Manual - Centers for Medicare ...
www.cms.govErythropoiesis Stimulating Agents (ESAs) 80.12 - Claims Processing Rules for ESAs Administered to Cancer Patients for Anti-Anemia Therapy. 90 - Claims Processing Rules for Hospital Outpatient Billing and Payment . 90.1 - Blood/Blood Products and Drugs Classified in Separate APCs for Hospital